David R. Webb

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

Bryan Williams, Thomas M. MacDonald, S. V. Morant et al. · The Lancet · 2015 · 1.2K citations · Full text

Discovery of Alogliptin:  A Potent, Selective, Bioavailable, and Efficacious Inhibitor of Dipeptidyl Peptidase IV

Jun Feng, Zhiyuan Zhang, Michael B. Wallace et al. · Journal of Medicinal Chemistry · 2007 · 399 citations · Full text

Plasma Dpp-4 Activity, Pharmacotherapy, Chemical Biology +17

Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure.

Joseph P. Noon, Brian R. Walker, David R. Webb et al. · Journal of Clinical Investigation · 1997 · 328 citations · Full text

Hypertension, Vascular Disease, Young Adults +20

Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies

Bryan Williams, Thomas M. MacDonald, S. V. Morant et al. · The Lancet Diabetes & Endocrinology · 2018 · 315 citations · Full text

Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation.

Brian R. Walker, A. A. Connacher, R M Lindsay et al. · The Journal of Clinical Endocrinology & Metabolism · 1995 · 266 citations

Glucocorticoid, Insulin Signaling, Molecular Pharmacology +18